These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 8354301)

  • 21. [In vitro comparative activity of norfloxacin in the comparison of pathogenic bacteria of the urinary tract].
    Carlone NA; Cuffini AM; Tullio V; Savoia D; Cavallo GP
    G Batteriol Virol Immunol; 1986; 79(1-6):85-97. PubMed ID: 3479370
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Are quinolone-resistant uropathogenic Escherichia coli less virulent?
    Vila J; Simon K; Ruiz J; Horcajada JP; Velasco M; Barranco M; Moreno A; Mensa J
    J Infect Dis; 2002 Oct; 186(7):1039-42. PubMed ID: 12232848
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trends in Quinolone Resistance Among Common Urinary Tract Isolates Over Three Years.
    Ahmed A; Bashir T
    J Coll Physicians Surg Pak; 2015 Jul; 25(7):543-5. PubMed ID: 26208565
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of subminimal inhibitory concentrations of three fluoroquinolones on adherence of uropathogenic strains of Escherichia coli.
    Baskin H; Doğan Y; Bahar IH; Yuluğ N
    Int J Antimicrob Agents; 2002 Jan; 19(1):79-82. PubMed ID: 11814773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activity of prulifloxacin against Escherichia coli isolated from urinary tract infections and the biological cost of prulifloxacin resistance.
    Gualco L; Schito AM; Schito GC; Marchese A
    Int J Antimicrob Agents; 2007 Jun; 29(6):679-87. PubMed ID: 17363225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The in-vitro comparative activity of quinolones against bacteria from urinary tract infections in general practice.
    Willems FT; Boerema JB; von Summeren TR
    J Antimicrob Chemother; 1986 Jan; 17(1):69-73. PubMed ID: 2936709
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of minimum inhibitory concentration values for fluoroquinolones against Escherichia coli causing urinary tract infection in both hospitalized patients and outpatients.
    Tayfour M; Yuce A; Yulug N
    Saudi Med J; 2001 Oct; 22(10):848-51. PubMed ID: 11744939
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Invasive disease caused by ciprofloxacin-resistant uropathogenic Escherichia coli.
    Blázquez R; Menasalvas A; Carpena I; Ramírez C; Guerrero C; Moreno S
    Eur J Clin Microbiol Infect Dis; 1999 Jul; 18(7):503-5. PubMed ID: 10482029
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of increase in resistance to quinolones in general practice isolates of Escherichia coli.
    Weber P; Plaisance JJ; Mancy C
    J Antimicrob Chemother; 1994 Jul; 34(1):187-8. PubMed ID: 7961211
    [No Abstract]   [Full Text] [Related]  

  • 30. Infections caused by Escherichia coli resistant to norfloxacin in hospitalized cirrhotic patients.
    Ortiz J; Vila MC; Soriano G; Miñana J; Gana J; Mirelis B; Novella MT; Coll S; Sábat M; Andreu M; Prats G; Solá R; Guarner C
    Hepatology; 1999 Apr; 29(4):1064-9. PubMed ID: 10094947
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Decreased invasive capacity of quinolone-resistant Escherichia coli in patients with urinary tract infections.
    Velasco M; Horcajada JP; Mensa J; Moreno-Martinez A; Vila J; Martinez JA; Ruiz J; Barranco M; Roig G; Soriano E
    Clin Infect Dis; 2001 Nov; 33(10):1682-6. PubMed ID: 11595990
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trimethoprim and ciprofloxacin resistance and prescribing in urinary tract infection associated with Escherichia coli: a multilevel model.
    Vellinga A; Tansey S; Hanahoe B; Bennett K; Murphy AW; Cormican M
    J Antimicrob Chemother; 2012 Oct; 67(10):2523-30. PubMed ID: 22729920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-level resistance to ciprofloxacin in Escherichia coli.
    Threlfall EJ; Cheasty T; Graham A; Rowe B
    Lancet; 1997 Feb; 349(9049):403. PubMed ID: 9033478
    [No Abstract]   [Full Text] [Related]  

  • 34. The changing pattern of antimicrobial resistance within 42,033 Escherichia coli isolates from nosocomial, community and urology patient-specific urinary tract infections, Dublin, 1999-2009.
    Cullen IM; Manecksha RP; McCullagh E; Ahmad S; O'Kelly F; Flynn RJ; McDermott T; Murphy P; Grainger R; Fennell JP; Thornhill JA
    BJU Int; 2012 Apr; 109(8):1198-206. PubMed ID: 21883861
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic effect of the quinolone prodrug prulifloxacin against experimental urinary tract infections in mice.
    Tomii Y; Ozaki M; Matsuda M; Honmura T; Nishimura I; Yamaguchi R; Adachi T; Okawa Y; Nishino T
    Arzneimittelforschung; 1996 Dec; 46(12):1169-73. PubMed ID: 9006794
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of ciprofloxacin on adhesive properties of non-P mannose-resistant uropathogenic Escherichia coli isolates.
    Balagué C; Fernández L; Pérez J; Grau R
    J Antimicrob Chemother; 2003 Feb; 51(2):401-4. PubMed ID: 12562710
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of low-level fluoroquinolone resistance genes qnrA1, qnrB19 and qnrS1 on ciprofloxacin treatment of isogenic Escherichia coli strains in a murine urinary tract infection model.
    Jakobsen L; Cattoir V; Jensen KS; Hammerum AM; Nordmann P; Frimodt-Møller N
    J Antimicrob Chemother; 2012 Oct; 67(10):2438-44. PubMed ID: 22685162
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Studies on the emergence of resistance to lomefloxacin in vitro.
    Kanematsu M; Greenwood D
    Eur J Clin Microbiol Infect Dis; 1989 Aug; 8(8):741-5. PubMed ID: 2506046
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of ciprofloxacin nonsusceptible urinary tract infections with ciprofloxacin.
    Jeffres MN; Shuster JE; Barclay SM
    Ann Pharmacother; 2011 Jun; 45(6):824-5. PubMed ID: 21666093
    [No Abstract]   [Full Text] [Related]  

  • 40. Evolution of fluoroquinolone resistance among Escherichia coli urinary tract isolates from a French university hospital: application of the dynamic regression model.
    Mahamat A; Lavigne JP; Fabbro-Peray P; Kinowski JM; Daurès JP; Sotto A
    Clin Microbiol Infect; 2005 Apr; 11(4):301-6. PubMed ID: 15760427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.